S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

Veradigm Stock Price, News & Analysis (NASDAQ:MDRX)

$10.07
-2.52 (-20.02%)
(As of 12/8/2023 ET)
Compare
Today's Range
$9.86
$12.25
50-Day Range
$10.07
$13.89
52-Week Range
$9.86
$19.77
Volume
8.75 million shs
Average Volume
867,048 shs
Market Capitalization
$1.10 billion
P/E Ratio
23.42
Dividend Yield
N/A
Price Target
$16.63

Veradigm MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
65.1% Upside
$16.63 Price Target
Short Interest
Bearish
10.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.26mentions of Veradigm in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.45%
From $0.67 to $0.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Business Services Sector

145th out of 292 stocks

Computer Integrated Systems Design Industry

13th out of 31 stocks


MDRX stock logo

About Veradigm Stock (NASDAQ:MDRX)

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Stock Price History

MDRX Stock News Headlines

Veradigm (NASDAQ:MDRX) Sets New 12-Month Low at $10.12
Veradigm (NASDAQ:MDRX) Research Coverage Started at StockNews.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Why Veradigm Shares Are Trading Lower
Veradigm Inc. Announces Leadership Transition
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Veradigm (MDRX) Faces Lawsuit for Inflating Revenues- Hagens Berman
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
12/09/2023
Next Earnings (Estimated)
12/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Target
$16.63
High Stock Price Target
$18.50
Low Stock Price Target
$13.00
Potential Upside/Downside
+65.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.20 per share
Book Value
$11.49 per share

Miscellaneous

Free Float
106,758,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
0.78

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Richard J. PoultonMr. Richard J. Poulton (Age 58)
    CEO & Director
    Comp: $2.45M
  • Ms. Tejal Vakharia (Age 49)
    Senior VP of Marketing & Government Affairs, General Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Mr. Thomas J. Langan (Age 57)
    President & CCO
  • Ms. Leah Jones (Age 50)
    Chief Financial Officer
  • Jenny Gelinas
    Vice President of Investor Relations
  • Mr. Richard Elmore
    Senior Vice President of Corporate Development & Strategy
  • Ms. Lisa Hammond C.P.C. (Age 50)
    Senior VP & Chief Human Resources Officer
  • Mr. John Sage
    Senior Vice President of U.S. Hospitals & Health Systems Sales
  • Mr. Elliot Bryant
    Senior VP & General Manager for Classic Client Solutions Business Unit
  • Mr. John Mayr
    Senior Vice President of Global Client Delivery Organization














MDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price target for 2024?

3 Wall Street analysts have issued 1-year price targets for Veradigm's shares. Their MDRX share price targets range from $13.00 to $18.50. On average, they expect the company's share price to reach $16.63 in the next year. This suggests a possible upside of 65.1% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2023?

Veradigm's stock was trading at $17.64 at the start of the year. Since then, MDRX stock has decreased by 42.9% and is now trading at $10.07.
View the best growth stocks for 2023 here
.

When is Veradigm's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 14th 2023.
View our MDRX earnings forecast
.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) posted its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to analyst estimates of $376.09 million. Veradigm's quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 earnings per share.

What ETFs hold Veradigm's stock?
What guidance has Veradigm issued on next quarter's earnings?

Veradigm updated its FY 2023 earnings guidance on Monday, September, 18th. The company provided earnings per share guidance of $0.80-$0.90 for the period, compared to the consensus earnings per share estimate of $0.87. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $638.08 million.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Who are Veradigm's major shareholders?

Veradigm's stock is owned by many different retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (4.00%), Wellington Management Group LLP (2.44%), Fuller & Thaler Asset Management Inc. (2.33%), Westfield Capital Management Co. LP (2.20%), Charles Schwab Investment Management Inc. (1.75%) and Northern Trust Corp (1.52%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends
.

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
This page (NASDAQ:MDRX) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -